Forchheim, Germany Clinical Trials

A listing of Forchheim, Germany clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 44 clinical trials
A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations

The purpose of this study is to evaluate efficacy of erdafitinib versus chemotherapy or pembrolizumab in participants with advanced urothelial cancer harboring selected fibroblast growth factor receptor (FGFR) aberrations who have progressed after 1 or 2 prior treatments, at least 1 of which includes an anti-PD-(L) 1 agent (cohort 1) …

pembrolizumab
erdafitinib
transitional cell carcinoma
adjuvant chemotherapy
docetaxel
Friedrich-Alexander Universitaet Urologische Universitaetskl
 (8.7 away) Contact site
  • 271 views
  • 12 Oct, 2020
  • +522 other locations
Short-course Radiotherapy Versus Chemoradiotherapy Followed by Consolidation Chemotherapy and Selective Organ Preservation for MRI-defined Intermediate and High-risk Rectal Cancer Patients

The hereby proposed ACO/ARO/AIO-18.1 randomized trial aims to directly compare the newly established TNT concepts applying either short-course RT according to RAPIDO, or CRT according to CAO/ARO/AIO-04/-12, both followed by consolidation chemotherapy, and surgery or a watch&wait (W&W) approach for patients with clinical complete response (cCR). The ACO/ARO/AIO-18.1 study incorporates …

University Clinic Erlangen
 (8.7 away) Contact site
  • 0 views
  • 02 Nov, 2020
  • +43 other locations
Dendritic Cells Plus Autologous Tumor RNA in Uveal Melanoma

Patients suffering from uveal melanoma (typed positive for monosomy 3 and without evidence for metastases) will be vaccinated over a period of 2 years with Dendritic Cell loaded with autologous Tumor RNA. 200 patients will be included. The Trial is an open multicenter Phase III Trial.

metastasis
therapeutic autologous dendritic cells
University Hospital Department of Ophtalmology
 (8.7 away) Contact site
  • 16 views
  • 12 Jan, 2020
  • +9 other locations
Dasatinib Holiday for Improved Tolerability

Treatment optimization for patients with chronic myeloid leukemia (CML) with treatment nave disease (1st line) and patients with resistance or intolerance against alternative Abl-Kinase Inhibitors (2nd line) (DasaHIT Trial (Dasatinib Holiday for Improved Tolerability))

ponatinib
dasatinib
hydroxyurea
leukemia
potassium
Gemeinschaftspraxis Erlangen
 (9.5 away) Contact site
  • 11 views
  • 16 Sep, 2020
  • +79 other locations
Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017

The understanding of acute lymphoblastic leukemia (ALL) in childhood and adolescence has largely changed due to extensive genetic research in recent years: ALL is now considered to be a very heterogeneous disease group. The leukemia cells present themselves with quite differently activated regulatory mechanisms of the malignant phenotype. The introduction …

cytarabine
dexamethasone
fludarabine
residual tumor
minimal residual disease
Universitaets - Kinderklinik
 (8.7 away) Contact site
  • 562 views
  • 27 Oct, 2020
  • +167 other locations
Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction

The primary objective is to determine if BIIB093 improves functional outcome at Day 90 as measured by the modified Rankin Scale (mRS) when compared with placebo in participants with Large Hemispheric Infarction (LHI). The secondary objectives are to determine if BIIB093 improves overall survival at Day 90 when compared with …

MRI
ischemic stroke
glibenclamide
infarct
glyburide
Research Site
 (9.4 away) Contact site
  • 213 views
  • 22 Sep, 2020
  • +209 other locations
Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)

Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. This study will evaluate how well risankizumab works compared to ustekinumab. This study will assess change in Crohn's Disease Activity Index (CDAI). Risankizumab is an investigational drug being developed for the treatment of …

ustekinumab
risankizumab
tumor necrosis factor
crohn's disease
abdominal pain
Universitaetsklinikum Erlangen /ID# 223404
 (8.7 away) Contact site
  • 97 views
  • 19 Nov, 2020
  • +295 other locations
A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

This is a study to demonstrate the clinical efficacy, safety and tolerability of bimekizumab administered subcutaneously (sc) compared with placebo in the treatment of subjects with active Psoriatic Arthritis (PsA).

adalimumab
hydroxychloroquine
steroidal anti-inflammatory drugs
sulfasalazine
rheumatoid factor
Pa0010 40023
 (9.4 away) Contact site
  • 235 views
  • 19 Nov, 2020
  • +306 other locations
A Study to Evaluate Further Therapeutic Strategies With Guselkumab in Participants With Moderate-to-Severe Plaque-Type Psoriasis

The purpose of this study is to demonstrate that Super-Responders (SRe; defined as psoriasis participants who receive on-label guselkumab treatment until week 20 and respond with a Psoriasis Area and Severity Index score (PASI) = 0 at weeks 20 and 28) maintain control of disease until week 68 with prolonged …

guselkumab
plaque psoriasis
tuberculosis
Universitaetsklinik Erlangen
 (8.7 away) Contact site
  • 15 views
  • 10 Sep, 2020
  • +197 other locations
Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)

A global study to evaluate peri-operative pembrolizumab with chemotherapy versus placebo to pembrolizumab plus chemotherapy in cisplatin eligible patients.

Universitaetsklinikum Erlangen ( Site 0505)
 (8.7 away) Contact site
  • 58 views
  • 25 Nov, 2020
  • +179 other locations